Respiratory syncytial virus infection+3
Not recruitingStudy on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older
Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older
- Disease:Respiratory syncytial virus infectionRespiratory syncytial virus bronchiolitis+2
- Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Germany- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
- Sponsor:GlaxoSmithKline Biologicals










